Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





METHOMYL								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 16752-77-5; **Chemical Formula:** C5H10N2O2S
OSHA formerly had no limit for methomyl. The ACGIH has a TLV-TWA of 2.5 mg/m3 for this white crystalline solid with a slightly sulfurous odor. The proposed PEL for methomyl was 2.5 mg/m3 as an 8-hour TWA; NIOSH (Ex. 8-47, Table N1) concurs, and the final rule establishes this limit.
Methomyl is a cholinesterase-inhibiting insecticide. The oral LD(50) in rats is reported to be between 25 and 40 mg/kg (Dashiell and Kennedy 1984/Ex. 1-548). Studies of dermal effects have reported no appreciable irritation or sensitization in guinea pigs. Instillation of a 10-percent solution of methomyl in propylene glycol or of the dry material into rabbit eyes caused mild conjunctivitis without corneal injury. However, marked pupillary constriction, a health effect produced commonly by cholinesterase inhibitors, was observed (E.I. du Pont de Nemours and Co., Inc., as cited in ACGIH 1986/Ex. 1-3, p. 363). The LC(50) of unformulated methomyl as mist is 0.3 mg/L at four-hour exposures; the lethal concentration in rats exposed to a 90-percent water-soluble formulation with a particle size of less than 10 microns was approximately 0.45 mg/L.
Inhalation studies have reported no fatalities resulting from four-hour exposures to the saturated vapor. There is no clinical evidence of cumulative toxicity resulting from 10 doses of 5.1 mg/kg/day over a 14-day period (Harvey, Jelinek, and Sherman 1973/Ex. 1-486). Methomyl is rapidly metabolized and excreted in the urine, and cholinesterase inhibition is thus quickly reversed. In dogs, a dose of 20 mg/kg (one-half the lethal dose) produced symptoms of intoxication and cholinesterase inhibition that disappeared within two to four hours after cessation of exposure (E.I. du Pont de Nemours and Co., Inc. as cited in ACGIH 1986/Ex. 1-3, p. 363). No depression of cholinesterase activity could be detected in rats fed at levels of 0, 200, 400, or 800 ppm methomyl for 79 days. In dogs, 90-day and two-year feeding studies showed no effects at 0, 50, 100, or 400 ppm; however, animals fed at 1000 ppm did demonstrate toxicity. Similar studies of rats have shown kidney, liver, and spleen damage at higher feeding levels, but the no-effect level for both rats and dogs has been reported to be 100 ppm (Kaplan and Sherman 1977/Ex. 1-337). Only NIOSH submitted comments on methomyl.
In the final rule, OSHA is establishing a PEL of 2.5 mg/m3 (8-hour TWA) for methomyl. The Agency concludes that this limit will protect exposed workers against the risk of cholinesterase inhibition to which they could formerly have been exposed in the absence of any OSHA limit. The Agency has determined that this limit will substantially reduce the significant risk of cholinergic effects, which constitute material impairments of health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue